Market Place
Sourcing Support
Eterna Therapeutics Regains Compliance with NASDAQ Listing
14 Nov 2024 //
GLOBENEWSWIRE
Eterna Therapeutics Completes Financial Restructuring
30 Oct 2024 //
GLOBENEWSWIRE
Eterna And Factor Bioscience Announce Cell Therapy Collaboration
17 Oct 2024 //
GLOBENEWSWIRE
Thomas Pigeon Joins Eterna Health As CMO
12 Aug 2024 //
GLOBENEWSWIRE
Eterna B2M-KO iMSC Data At ASGCT 2024
10 May 2024 //
GLOBENEWSWIRE
Eterna Appoints Mahendra Rao To Scientific Advisory Board
08 May 2024 //
GLOBENEWSWIRE
Eterna On B2M-KO iMSC Line With Immunosuppressive Activity At ASGCT
07 May 2024 //
GLOBENEWSWIRE
Eterna To Present On iPSC Line Mimicking B2M Expression At ASGCT
07 May 2024 //
GLOBENEWSWIRE
Eterna Announces the Appointment of Peter Cicala, JD, to its Board of Directors
20 Feb 2024 //
GLOBENEWSWIRE
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award
03 Jan 2024 //
GLOBENEWSWIRE
Eterna Names Sanjeev Luther as President and Chief Executive Officer
20 Dec 2023 //
GLOBENEWSWIRE
Eterna Therapeutics Announces $9.2 Million Convertible Debt & Warrant Financing
14 Dec 2023 //
GLOBENEWSWIRE
Eterna Therapeutics Appoints James Bristol to Board of Directors
01 Nov 2023 //
GLOBENEWSWIRE
Lineage Announces Initiation of Activities for Hypoimmune Pluripotent Cell Line
06 Sep 2023 //
BUSINESSWIRE
Eterna Announces Initiation of Activities for Hypoimmune Pluripotent Cell Line
06 Sep 2023 //
GLOBENEWSWIRE
Eterna Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
05 Sep 2023 //
GLOBENEWSWIRE
Eterna Announces Completion of $8.7 Million of Convertible Debt Financing
18 Jul 2023 //
GLOBENEWSWIRE
Eterna Appoints Brant Binder and Richard Wagner, Ph.D. to Board of Directors
11 Jul 2023 //
GLOBENEWSWIRE
Eterna Appoints Megan Yung as Chief Strategy Officer, General Counsel
24 May 2023 //
GLOBENEWSWIRE
Eterna and Factor Announce New Data on Multi-Cell-Type Therapeutic
17 May 2023 //
GLOBENEWSWIRE
Eterna Therapeutics to Deliver Eight Presentations at the ASGCT (ASGCT)
04 May 2023 //
GLOBENEWSWIRE
Eterna Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
02 May 2023 //
GLOBENEWSWIRE
Eterna Therapeutics & Lincoln Park Capital Enter into a Agreement for Up To $10M
11 Apr 2023 //
GLOBENEWSWIRE
Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board
28 Mar 2023 //
GLOBENEWSWIRE
Eterna Reports Financial Results for Fourth Quarter and Full Year 2022
20 Mar 2023 //
GLOBENEWSWIRE
Eterna Therapeutics Enters Into Agreement with Lineage Cell Therapeutics
22 Feb 2023 //
GLOBENEWSWIRE
Eterna Announces Research Collaboration to Develop Advanced Gene-Edited Ips
01 Nov 2022 //
GLOBENEWSWIRE
